Feb 8, 2026 Tired of conflicting information about switching from tirzepatide to semaglutide
New real-world evidence suggests that staying on GLP-1 therapy may be critical for sustaining cardiovascular protection, while even short interruptions could diminish long-term benefits in people with type 2 diabetes
The non-specific melanocortin peptide agonist setmelanotide, which acts via the MC4R to inhibit food intake and produce weight loss, has been approved by the FDA for the treatment of proopiomelanocortin deficiency, leptin receptor deficiency and BardetBiedl syndrome
Patients taking tirzepatide alongside insulin or sulfonylureas face the highest risk, but even those on tirzepatide monotherapy should be cautious
Two recent large-scale studies hinted that semaglutide treatment worsened diabetic retinopathy temporarily, related to blood sugar lowering quickly
Helpful context before the funnel FormBlends Editorial Context Reviewed May 14, 2026 Retatrutide for Seniors Over 65